Anti-Cxcr6 Treatment For Myocarditis

Invention Novelty

Value Proposition

Technology Description

Researchers at UCSF have developed a novel tantibody treatment to address myocarditis, a serious cardiac inflammatory condition that currently has no FDA-approved treatments. The technology is in pre-clinical development, with successful proof-of-concept studies demonstrating that the treatment can rescue cardiac inflammation in mouse models of immune checkpoint inhibitor-induced myocarditis. What makes this approach particularly innovative is its targeting of a subset of T-cells that have been identified as key mediators of cardiac inflammation in both human patients and animal models. While other companies may be exploring similar therapies for different indications, this represents the first known application of this therapeutic mechanism specifically for cardiac inflammation, potentially offering a revolutionary treatment option for patients suffering from myocarditis and related inflammatory heart conditions.

Application

Looking for Partners

Stage of Development

Related Materials

Data Availability

Patent Status

Patent Pending